Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 3 · 37.5%Moderate 3 · 37.5%High 1 · 12.5%

Anticoagulant vs different dose of the same anticoagulant

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 278 participants
Moderate

Anticoagulant vs placebo or no treatment

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.04, 3.61]
5 studies · 1777 participants
Low

Anticoagulant vs antiplatelet agent

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Moderate

Anticoagulant vs no treatment

All‐cause mortality · people hospitalised with COVID‐19

It is very uncertain whether anticoagulants changes all‐cause mortality compared with no treatment (very low certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 0.64 [0.55, 0.74]
3 studies · 8395 participants
Very low

Higher‐dose anticoagulants vs lower‐dose anticoagulants

All‐cause mortality · people hospitalised with COVID‐19

Higher‐dose anticoagulants showed no clear difference in all‐cause mortality compared with lower‐dose anticoagulants (high certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 1.03 [0.92, 1.16]
4 studies · 4489 participants
High

DOAC vs variable dose warfarin

All‐cause mortality · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in all‐cause mortality compared with warfarin (moderate certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.05]
4 studies · 9595 participants
Moderate

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

All‐cause mortality · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.97 [0.83, 1.14]
5 studies · 2854 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
4 studies · 1060 participants
Low